AF
BMRN icon

Alerus Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Alerus Financial’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.2K Hold
1,000
– – ﹤0.01% 300
2026
Q1 		$56.5K Hold
1,000
– – ﹤0.01% 293
2025
Q4 		$59.4K Hold
1,000
– – ﹤0.01% 230
2025
Q3 		$54.2K Hold
1,000
– – ﹤0.01% 258
2025
Q2 		$55K Buy
+1,000
New +$58.9K ﹤0.01% 239

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Alerus Financial's BMRN Position: Q2 2026 in Review

Alerus Financial held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 1,000 shares worth $57.2K. The position accounts for ﹤0.01% of the portfolio, ranked #300.

Alerus Financial first reported a position in BMRN in Q2 2025 and has held it in 5 quarters since. The position peaked at $59.4K in Q4 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Alerus Financial held 1,000 shares of BioMarin Pharmaceuticals worth $57.2K as of Q2 2026.
  • Alerus Financial left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Alerus Financial's portfolio in Q2 2026, its #300 holding.
  • Alerus Financial first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Alerus Financial's BioMarin Pharmaceuticals position peaked at $59.4K in Q4 2025.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Alerus Financial's 13F filing for Q2 2026, filed 14 Aug 2026.